IL188072D0 - Process for manufacturing vaccines - Google Patents

Process for manufacturing vaccines

Info

Publication number
IL188072D0
IL188072D0 IL188072A IL18807207A IL188072D0 IL 188072 D0 IL188072 D0 IL 188072D0 IL 188072 A IL188072 A IL 188072A IL 18807207 A IL18807207 A IL 18807207A IL 188072 D0 IL188072 D0 IL 188072D0
Authority
IL
Israel
Prior art keywords
process
manufacturing vaccines
vaccines
manufacturing
Prior art date
Application number
IL188072A
Other versions
IL188072A (en
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to GBGB0513069.5A priority Critical patent/GB0513069D0/en
Priority to GBGB0513071.1A priority patent/GB0513071D0/en
Priority to GB0515556A priority patent/GB0515556D0/en
Priority to GB0524204A priority patent/GB0524204D0/en
Priority to GB0526041A priority patent/GB0526041D0/en
Priority to GB0526040A priority patent/GB0526040D0/en
Priority to PCT/EP2006/006270 priority patent/WO2007000343A2/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36716943&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL188072(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of IL188072D0 publication Critical patent/IL188072D0/en
Publication of IL188072A publication Critical patent/IL188072A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0016Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0017Combination vaccines based on whole cell diphtheria-tetanus-pertussis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0016Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/05Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/08Clostridium, e.g. Clostridium tetani
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092Streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/095Neisseria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/099Bordetella
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/102Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/116Polyvalent bacterial antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/29Hepatitis virus
    • A61K39/292Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/04Drugs for disorders of the respiratory system for throat disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/62Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/62Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse Transcribing DNA Viruses
    • C12N2730/00011Reverse Transcribing DNA Viruses
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense
    • C12N2760/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense ssRNA Viruses negative-sense
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16211Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense
    • C12N2760/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense ssRNA Viruses negative-sense
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16211Influenzavirus B, i.e. influenza B virus
    • C12N2760/16271Demonstrated in vivo effect
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses positive-sense
    • C12N2770/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses positive-sense ssRNA Viruses positive-sense
    • C12N2770/32011Picornaviridae
    • C12N2770/32611Poliovirus
    • C12N2770/32634Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/46Medical treatment of waterborne diseases characterized by the agent
    • Y02A50/462The waterborne disease being caused by a virus
    • Y02A50/465The waterborne disease being caused by a virus the virus being the poliovirus, i.e. Poliomyelitis or Polio
    • Y02A50/466The waterborne disease being caused by a virus the virus being the poliovirus, i.e. Poliomyelitis or Polio the medicinal preparation containing antigens or antibodies, e.g. vaccines, antisera
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/46Medical treatment of waterborne diseases characterized by the agent
    • Y02A50/468The waterborne disease being caused by a bacteria
    • Y02A50/471The waterborne disease being caused by a bacteria the bacteria being Vibrio cholerae, i.e. Cholera
    • Y02A50/472The waterborne disease being caused by a bacteria the bacteria being Vibrio cholerae, i.e. Cholera the medicinal preparation containing antigens or antibodies, e.g. vaccines, antisera
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/46Medical treatment of waterborne diseases characterized by the agent
    • Y02A50/468The waterborne disease being caused by a bacteria
    • Y02A50/481The waterborne disease being caused by a bacteria of the genus Salmonella, i.e. Salmonellosis
    • Y02A50/483The waterborne disease being caused by a bacteria of the genus Salmonella, i.e. Salmonellosis the bacteria being Salmonella typhi, i.e. Typhoid fever
    • Y02A50/484The waterborne disease being caused by a bacteria of the genus Salmonella, i.e. Salmonellosis the bacteria being Salmonella typhi, i.e. Typhoid fever the medicinal preparation containing antigens or antibodies, e.g. vaccines, antisera
IL188072A 2005-06-27 2007-12-12 Method of conjugating a saccharide to a protein carrier using carbodiimide condensation chemistry IL188072A (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GBGB0513069.5A GB0513069D0 (en) 2005-06-27 2005-06-27 Immunogenic composition
GBGB0513071.1A GB0513071D0 (en) 2005-06-27 2005-06-27 Immunogenic composition
GB0515556A GB0515556D0 (en) 2005-07-28 2005-07-28 Immunogenic composition
GB0524204A GB0524204D0 (en) 2005-11-28 2005-11-28 Immunogenic composition
GB0526040A GB0526040D0 (en) 2005-12-21 2005-12-21 Immunogenic composition
GB0526041A GB0526041D0 (en) 2005-12-21 2005-12-21 Immunogenic composition
PCT/EP2006/006270 WO2007000343A2 (en) 2005-06-27 2006-06-23 Process for manufacturing vaccines

Publications (2)

Publication Number Publication Date
IL188072D0 true IL188072D0 (en) 2008-03-20
IL188072A IL188072A (en) 2017-07-31

Family

ID=36716943

Family Applications (8)

Application Number Title Priority Date Filing Date
IL187924A IL187924A (en) 2005-06-27 2007-12-06 Immunogenic compositions with n. meningitidis capsular polysaccharides, vaccines and kits including them, processes to make them and their use in manufacture of medicines
IL188046A IL188046A (en) 2005-06-27 2007-12-11 Immunogenic composition comprising at least two different saccharide conjugates
IL188045A IL188045D0 (en) 2005-06-27 2007-12-11 Immunogenic composition
IL188072A IL188072A (en) 2005-06-27 2007-12-12 Method of conjugating a saccharide to a protein carrier using carbodiimide condensation chemistry
IL213718A IL213718A (en) 2005-06-27 2011-06-22 Immunogenic composition comprising at least two different saccharides conjugated separately to the same type of carrier protein and vaccine comprising such composition
IL213795A IL213795A (en) 2005-06-27 2011-06-28 Immunogenic composition comprising at least two different saccharides and vaccine comprising said immunogenic composition
IL214657A IL214657D0 (en) 2005-06-27 2011-08-15 Immunogenic composition
IL222346A IL222346A (en) 2005-06-27 2012-10-11 Immunogenic composition comprising at least two different n meningitides capsular saccharides, uses thereof and a vaccine comprising the same

Family Applications Before (3)

Application Number Title Priority Date Filing Date
IL187924A IL187924A (en) 2005-06-27 2007-12-06 Immunogenic compositions with n. meningitidis capsular polysaccharides, vaccines and kits including them, processes to make them and their use in manufacture of medicines
IL188046A IL188046A (en) 2005-06-27 2007-12-11 Immunogenic composition comprising at least two different saccharide conjugates
IL188045A IL188045D0 (en) 2005-06-27 2007-12-11 Immunogenic composition

Family Applications After (4)

Application Number Title Priority Date Filing Date
IL213718A IL213718A (en) 2005-06-27 2011-06-22 Immunogenic composition comprising at least two different saccharides conjugated separately to the same type of carrier protein and vaccine comprising such composition
IL213795A IL213795A (en) 2005-06-27 2011-06-28 Immunogenic composition comprising at least two different saccharides and vaccine comprising said immunogenic composition
IL214657A IL214657D0 (en) 2005-06-27 2011-08-15 Immunogenic composition
IL222346A IL222346A (en) 2005-06-27 2012-10-11 Immunogenic composition comprising at least two different n meningitides capsular saccharides, uses thereof and a vaccine comprising the same

Country Status (35)

Country Link
US (13) US8398983B2 (en)
EP (11) EP1896062B1 (en)
JP (9) JP5280199B2 (en)
KR (7) KR101351873B1 (en)
CN (3) CN102526723B (en)
AP (1) AP2436A (en)
AR (3) AR056396A1 (en)
AT (3) AT462444T (en)
AU (7) AU2006263936B2 (en)
BR (5) BRPI0612669B1 (en)
CA (5) CA2612963C (en)
CY (4) CY1109996T1 (en)
DE (1) DE602006013313D1 (en)
DK (7) DK2351578T3 (en)
EA (4) EA013374B1 (en)
ES (7) ES2340711T3 (en)
HK (4) HK1114011A1 (en)
HR (4) HRP20100211T1 (en)
HU (4) HUE031380T2 (en)
IL (8) IL187924A (en)
LT (1) LT2351578T (en)
LU (1) LU92085I9 (en)
MA (4) MA29602B1 (en)
MX (5) MX2007016403A (en)
MY (3) MY148110A (en)
NL (1) NL300549I2 (en)
NO (4) NO344452B1 (en)
NZ (6) NZ564371A (en)
PE (6) PE20110096A1 (en)
PL (7) PL1896061T3 (en)
PT (7) PT2351578T (en)
SI (7) SI1896061T1 (en)
TW (5) TW201336507A (en)
UA (2) UA95238C2 (en)
WO (6) WO2007000343A2 (en)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100837917B1 (en) * 2000-06-29 2008-06-13 글락소스미스클라인 바이오로지칼즈 에스.에이. Multivalent vaccine composition
MX339524B (en) 2001-10-11 2016-05-30 Wyeth Corp Novel immunogenic compositions for the prevention and treatment of meningococcal disease.
EP1587537B1 (en) 2003-01-30 2012-04-11 Novartis AG Injectable vaccines against multiple meningococcal serogroups
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
NZ564371A (en) 2005-06-27 2010-05-28 Glaxosmithkline Biolog Sa Immunogenic composition comprising Hib saccharide conjugate and at least two further bacterial saccharide conjugates
AU2012261764B2 (en) * 2005-09-01 2016-09-08 Novartis Vaccines And Diagnostics Gmbh & Co. Kg Multiple vaccination including serogroup C meningococcus
BRPI0615420A2 (en) * 2005-09-01 2011-05-17 Novartis Vaccines & Diagnostic multiple vaccination including serogroup c meningococcus
CN101374548B (en) 2005-12-22 2013-05-01 葛兰素史密丝克莱恩生物有限公司 Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
US20090098156A1 (en) * 2006-03-22 2009-04-16 Lisa Danzig Regimens for immunisation with meningococcal conjugates
TR201807355T4 (en) * 2006-03-22 2018-06-21 Glaxosmithkline Biologicals Sa immunization with meningococcal conjugate regimes.
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
DK2066344T3 (en) 2006-09-07 2011-09-05 Glaxosmithkline Biolog Sa Inactivated Poliovirus combination vaccine
AR064642A1 (en) 2006-12-22 2009-04-15 Wyeth Corp Polynucleotide vector that comprises recombinant cell comprising the vector polypeptide, antibody, composition comprising the polynucleotide, vector, polypeptide or antibody recombinant cell, using the composition and method for preparing the same composition and prepare a composi
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0700135D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
CN101784282B (en) * 2007-06-26 2015-07-08 葛兰素史密丝克莱恩生物有限公司 Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
US20160228500A9 (en) * 2007-07-23 2016-08-11 Martina Ochs Immunogenic Polypeptides and Monoclonal Antibodies
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
DK2200642T3 (en) 2007-10-19 2012-07-16 Novartis Ag Meningococvaccinepræparater
EP2328613A1 (en) * 2008-08-28 2011-06-08 GlaxoSmithKline Biologicals S.A. Vaccine
DK2349520T3 (en) 2008-10-27 2016-08-15 Glaxosmithkline Biologicals Sa Purification Procedure for Group A Streptococcus Carbohydrate
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
WO2010070453A2 (en) 2008-12-17 2010-06-24 Novartis Ag Meningococcal vaccines including hemoglobin receptor
JP5597245B2 (en) 2009-03-24 2014-10-01 ノバルティス アーゲー N. meningitidis factor H binding protein with adjuvant
CA2756533A1 (en) 2009-03-24 2010-09-30 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
JP5593626B2 (en) * 2009-03-31 2014-09-24 凸版印刷株式会社 Measuring spoon
WO2010119343A2 (en) 2009-04-14 2010-10-21 Novartis Ag Compositions for immunising against staphylococcus aureus
EP2424562B1 (en) * 2009-04-30 2015-10-07 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
GB0910046D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
CA2766418C (en) * 2009-06-22 2016-03-29 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
AR078601A1 (en) 2009-06-22 2011-11-23 Wyeth Llc Immunogenic compositions of staphylococcus aureus antigens
EP2459216B1 (en) 2009-09-02 2013-10-30 Novartis AG Immunogenic compositions including tlr activity modulators
EP2475385A1 (en) 2009-09-10 2012-07-18 Novartis AG Combination vaccines against respiratory tract diseases
ES2626416T3 (en) * 2009-10-30 2017-07-25 Glaxosmithkline Biologicals Sa Purification of capsular saccharides of Staphilococcus aureus type 5 and type 8
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
WO2011080595A2 (en) 2009-12-30 2011-07-07 Novartis Ag Polysaccharide immunogens conjugated to e. coli carrier proteins
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201003924D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
CA2803239A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
CN107961367A (en) 2010-08-23 2018-04-27 惠氏有限责任公司 Make the stabilized method of effect of LP2086 (fHBP) subtribe B polypeptides in immunogenic composition
EA201390341A1 (en) 2010-09-01 2013-08-30 Новартис Аг Adsorption of immunote potentiators on insoluble salts of metals
PE20140173A1 (en) 2010-09-10 2014-02-20 Wyeth Llc Not lipidated antigen variants orf2086 of Neisseria meningitidis
ES2759484T3 (en) 2010-09-10 2020-05-11 Glaxosmithkline Biologicals Sa Meningococcus that overexpresses NadA and / or NHBA and external membrane vesicles derived from it
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
EP2680885B8 (en) 2011-03-02 2018-07-25 GlaxoSmithKline Biologicals SA Combination vaccines with lower doses of antigen and/or adjuvant
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
RU2636350C2 (en) 2011-11-07 2017-11-22 Новартис Аг MOLECULE CONTAINING spr0096 AND spr2021
JP2013112653A (en) * 2011-11-30 2013-06-10 Jnc Corp New polymer and process for producing the same
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
WO2013098589A1 (en) 2011-12-29 2013-07-04 Novartis Ag Adjuvanted combinations of meningococcal factor h binding proteins
CA2863178A1 (en) * 2012-01-30 2013-08-08 Serum Institute Of India Ltd. Immunogenic composition
CN104114706A (en) 2012-02-02 2014-10-22 诺华股份有限公司 Promoters for increased protein expression in meningococcus
CN102569723A (en) * 2012-02-13 2012-07-11 华为技术有限公司 Lithium ion battery positive electrode material and preparation method thereof, positive electrode and lithium ion battery
WO2013131983A1 (en) 2012-03-07 2013-09-12 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
US9375471B2 (en) 2012-03-08 2016-06-28 Glaxosmithkline Biologicals Sa Adjuvanted formulations of booster vaccines
JP2015509963A (en) 2012-03-08 2015-04-02 ノバルティス アーゲー Combination vaccine containing a TLR4 agonist
US10196429B2 (en) 2012-03-09 2019-02-05 Pfizer Inc. Neisseria meningitidis composition and methods thereof
CA3066792A1 (en) 2012-03-09 2013-09-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
KR102057217B1 (en) 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 Multivalent pneumococcal polysaccharide-protein conjugate composition
JP6324961B2 (en) 2012-09-06 2018-05-16 ノバルティス アーゲー Combination vaccine of serogroup B meningococcus and D / T / P
ITMI20121597A1 (en) 2012-09-25 2014-03-26 Beta Pharma S A Conjugate between fragment of the bacterial cell wall and a vehicle mucopolisaccaridico and its uses in the medical field
TR201808684T4 (en) 2012-10-02 2018-07-23 Glaxosmithkline Biologicals Sa Non-linear saccharide conjugates.
DK2925355T3 (en) 2012-11-30 2018-01-15 Glaxosmithkline Biologicals Sa Pseudomonas antigenes and antigen combinations
KR20140075196A (en) 2012-12-11 2014-06-19 에스케이케미칼주식회사 Multivalent pneumococcal polysaccharide-protein conjugate composition
BR112015014250A2 (en) 2012-12-18 2017-07-11 Glaxosmithkline Biologicals Sa method to immunize a baby, combination vaccine and kit
WO2014118305A1 (en) 2013-02-01 2014-08-07 Novartis Ag Intradermal delivery of immunological compositions comprising toll-like receptor agonists
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
CN105188743A (en) * 2013-03-18 2015-12-23 葛兰素史密丝克莱恩生物有限公司 Method of treatment
RU2662968C2 (en) 2013-09-08 2018-07-31 Пфайзер Инк. Immunogenic composition for neisseria meningitidis (options)
IN2014DE02450A (en) 2013-09-25 2015-06-26 Suzuki Motor Corp
RU2535122C1 (en) * 2013-11-06 2014-12-10 Федеральное казенное учреждение здравоохранения "Российский научно-исследовательский противочумный институт "Микроб" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека ("РосНИПЧИ "Микроб") Method for preparing choleragen anatoxin
JP6335326B2 (en) * 2014-01-21 2018-05-30 ファイザー・インク Immunogenic compositions containing conjugated capsular saccharide antigens and uses thereof
EP2921856B1 (en) 2014-03-18 2016-09-14 Serum Institute Of India Private Limited A quantitative assay for 4-pyrrolidinopyridine (4-ppy) in polysaccharide-protein conjugate vaccines
US10407703B2 (en) 2014-04-17 2019-09-10 Medizinische Hochschule Hannover Means and methods for producing Neisseria meningitidis capsular polysaccharides of low dispersity
BR112018000087A2 (en) * 2015-07-21 2018-09-04 Pfizer immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising them and uses thereof
MX2018010920A (en) * 2016-03-15 2019-03-06 Msd Wellcome Trust Hilleman Laboratories Pvt Ltd Novel polysaccharide-protein conjugates and process to obtain thereof.
KR20190044663A (en) * 2016-09-02 2019-04-30 사노피 파스퇴르 인크 Neisseria meningitis vaccine
EP3506933A2 (en) 2016-09-02 2019-07-10 GlaxoSmithKline Biologicals SA Vaccines for neisseria gonorrhoeae
PE20191107A1 (en) 2017-01-31 2019-08-26 Pfizer Neisseria meningitidis compositions and respective methods
WO2019145981A1 (en) * 2018-01-29 2019-08-01 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Novel meningococcal vaccine composition and process thereof
WO2019198096A1 (en) * 2018-04-11 2019-10-17 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Tetravalent meningococcal vaccine composition and process to prepare thereof

Family Cites Families (172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB513069A (en) 1937-04-24 1939-10-03 Linde Air Prod Co Improvements in method of and apparatus for the treatment of metallic bodies by oxidising gas
GB505518A (en) 1938-02-03 1939-05-12 Daniel Morgan Skeins Improvements in or relating to envelopes
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4123520A (en) * 1977-08-01 1978-10-31 Merck & Co., Inc. Method for preparing high molecular weight meningococcal Group C vaccine
US4235994A (en) * 1978-06-26 1980-11-25 Merck & Co., Inc. High molecular weight meningococcal group C vaccine and method for preparation thereof
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
DE3071552D1 (en) 1979-09-21 1986-05-22 Hitachi Ltd Semiconductor switch
DE3040825A1 (en) 1980-10-30 1982-09-09 Thomae Gmbh Dr K New tridecapeptide, process for its production and use
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) * 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
HU193083B (en) * 1984-02-22 1987-08-28 Sandoz Ag Process for preparing diazepinoindole derivatives further pharmaceutical compositions containing such compounds
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
IT1187753B (en) 1985-07-05 1987-12-23 Sclavo Spa Glycoprotein conjugate to attivita 'trivalent immunogenic
DE3526940C2 (en) 1985-07-27 1988-10-20 Siegfried 7135 Wiernsheim De Fricker
IL78929D0 (en) 1985-07-29 1986-09-30 Abbott Lab Microemulsion compositions for parenteral administration
US4727136A (en) 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
JPH01125328A (en) 1987-07-30 1989-05-17 Centro Natl De Biopreparados Neisseria meningitidis vaccine
US5180815A (en) 1988-04-13 1993-01-19 Fuji Photo Film Co., Ltd. Modified protein for carrying hapten
WO1989011813A1 (en) 1988-05-31 1989-12-14 KÖNIG-HAUG, Beatrice Shelving system
DE3841091A1 (en) 1988-12-07 1990-06-13 Behringwerke Ag Synthetic antigens, method for their production and their use
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
CA2063271A1 (en) 1989-07-14 1991-01-15 Subramonia Pillai Cytokine and hormone carriers for conjugate vaccines
IT1237764B (en) 1989-11-10 1993-06-17 Eniricerche Spa Synthetic peptides useful as universal carriers for the preparation of immunogenic conjugates and their use for the development of synthetic vaccines.
AU641715B2 (en) 1989-12-14 1993-09-30 National Research Council Of Canada Improved meningococcal polysaccharide conjugate vaccine
SE466259B (en) 1990-05-31 1992-01-20 Arne Forsgren Protein D - an IgD-binding protein FROM Haemophilus influenzae, and anvaendning this Foer analysis, vaccines and uppreningsaendamaal
IL98715D0 (en) 1990-08-13 1992-07-15 American Cyanamid Co Filamentous hemaglutinin of bodetella pertussis as a carrier molecule for conjugate vaccines
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
CA2059693C (en) 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
GB2264352A (en) 1992-01-31 1993-08-25 Richards Eng Ltd Incineration apparatus
WO1993015760A1 (en) 1992-02-11 1993-08-19 U.S. Government, As Represented By The Secretary Of The Army Dual carrier immunogenic construct
IT1262896B (en) 1992-03-06 1996-07-22 Compounds conjugates formed by heat shock proteins (hsp) poly- and oligo-saccharides, their use for the production of vaccines.
AU4230493A (en) * 1992-05-06 1993-11-29 President And Fellows Of Harvard College Diphtheria toxin receptor-binding region
RU2160120C2 (en) 1992-05-23 2000-12-10 Смитклайн Бичам Байолоджикалс С.А. Combined vaccine based on surface hepatitis b virus antigen, method of preparation thereof, and method for preventing hepatitis b infection in man
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
DE69323264D1 (en) 1992-10-27 1999-03-11 American Cyanamid Co Pediatric combination vaccine with improved immunogenicity of each vaccine component
JPH11502820A (en) 1995-03-22 1999-03-09 ヘンリー エム.ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン Production of immunogenic constructs using soluble carbohydrates activated by an organic cyanating reagent
US5849301A (en) * 1993-09-22 1998-12-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Producing immunogenic constructs using soluable carbohydrates activated via organic cyanylating reagents
DE69433341T2 (en) 1993-09-22 2004-04-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method for activating soluble carbohdrates by using new cyanylation reagents, for the production of immunogenic constructs
US5869058A (en) 1994-05-25 1999-02-09 Yeda Research And Development Co. Ltd. Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US5917017A (en) * 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
GB9422096D0 (en) * 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
DE69637597D1 (en) 1995-06-07 2008-08-21 Glaxosmithkline Biolog Sa Vaccine with a polysaccharide antigen-carrier protein conjugate and free carrier protein
ES2325301T3 (en) 1995-06-23 2009-09-01 Glaxosmithkline Biologicals S.A. Vaccine composition that includes a conjugated polisacaride antigen, adsorbed on aluminum phosphate.
SE9601158D0 (en) 1996-03-26 1996-03-26 Stefan Svenson Method of producing immunogenic products and vaccines
DE69712219T2 (en) 1996-10-23 2002-12-12 Matsushita Electric Ind Co Ltd Optical plate
AT348887T (en) 1996-10-31 2007-01-15 Human Genome Sciences Inc Streptococcus pneumoniae antigenes and vaccines
AU1420897A (en) 1996-12-18 1998-07-15 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Conjugate vaccine for (salmonella paratyphi) a
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
FR2763244B1 (en) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Multivalent vaccine composition with mixed carrier
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
EP1028750B1 (en) 1997-09-15 2006-02-01 Sanofi Pasteur MSD Method for preparing multivalent vaccines
AU9399498A (en) 1997-09-18 1999-04-05 Trustees Of The University Of Pennsylvania, The Receptor-binding pocket mutants of influenza a virus hemagglutinin for use in targeted gene delivery
US5965714A (en) 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
CA2264970A1 (en) 1998-03-10 1999-09-10 American Cyanamid Company Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria
GB9806456D0 (en) 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
GB9808932D0 (en) * 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
WO1999055715A2 (en) * 1998-04-28 1999-11-04 Galenica Pharmaceuticals, Inc. Polysaccharide-antigen conjugates
WO2000010599A2 (en) 1998-08-19 2000-03-02 North American Vaccine, Inc. IMMUNOGENIC β-PROPIONAMIDO-LINKED POLYSACCHARIDE PROTEIN CONJUGATE USEFUL AS A VACCINE PRODUCED USING AN N-ACRYLOYLATED POLYSACCHARIDE
WO2000033882A1 (en) 1998-12-04 2000-06-15 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services A vi-repa conjugate vaccine for immunization against salmonella typhi
PT1140157E (en) 1998-12-21 2009-05-06 Medimmune Inc Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
US6146902A (en) 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
DE60020677T2 (en) 1999-02-26 2006-05-04 Chiron Corp., Emeryville Microemulsions with adsorbed macromolecules and microparticles
NZ513841A (en) * 1999-03-19 2001-09-28 Smithkline Beecham Biolog S Vaccine against Streptococcus pneumoniae
EP1165796A2 (en) 1999-04-09 2002-01-02 Department of Health and Human Services Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
AT466928T (en) 1999-06-25 2010-05-15 Wyeth Corp Preparation of the lipid-modified form of peptidoglycan associated lipoprotein from gramnegative bacteria
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB9925559D0 (en) 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
WO2001041800A2 (en) 1999-12-02 2001-06-14 Chiron Corporation Compositions and methods for stabilizing biological molecules upon lyophilization
FR2806304B1 (en) * 2000-03-17 2002-05-10 Aventis Pasteur Polysaccharidic conjugates of pneumococcus for vaccine use against tetanus and diphtheria
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
KR100837917B1 (en) * 2000-06-29 2008-06-13 글락소스미스클라인 바이오로지칼즈 에스.에이. Multivalent vaccine composition
EP1322328B1 (en) * 2000-07-27 2014-08-20 Children's Hospital & Research Center at Oakland Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
EP2277896A1 (en) 2000-10-27 2011-01-26 Novartis Vaccines and Diagnostics S.r.l. Nucleic acids and proteins from streptococcus groups A & B
BR0206672A (en) * 2001-01-23 2005-05-10 Aventis Pasteur Multivalent meningococcal polysaccharide protein conjugate vaccine
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
AU2002309706A1 (en) 2001-05-11 2002-11-25 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
US6615062B2 (en) 2001-05-31 2003-09-02 Infraredx, Inc. Referencing optical catheters
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
USRE45137E1 (en) * 2001-10-03 2014-09-16 Novartis Vaccines And Diagnostics, Inc. Adjuvanted meningococcus compositions
MX339524B (en) * 2001-10-11 2016-05-30 Wyeth Corp Novel immunogenic compositions for the prevention and treatment of meningococcal disease.
CU23031A1 (en) * 2002-01-24 2005-02-23 Ct Ingenieria Genetica Biotech The surface antigen Hepatitis B Virus as mucosal immunopotentiator resulting formulations
US7615229B2 (en) * 2002-03-15 2009-11-10 Wyeth Holdings Corporation Mutants of the P4 protein of nontypable Haemophilus influenzae with reduced enzymatic activity
MXPA04009339A (en) * 2002-03-26 2005-01-25 Chiron Srl Modified saccharides having improved stability in water.
GB0210128D0 (en) * 2002-05-02 2002-06-12 Chiron Spa Nucleic acids and proteins from streptococcus groups A & B
DE60328481D1 (en) * 2002-05-14 2009-09-03 Novartis Vaccines & Diagnostic Sleep-capacitive vaccine containing the adjuvanz chitosan and menigokokkenantigene
CN1684707B (en) 2002-05-14 2012-09-05 诺华疫苗和诊断有限公司 Mucosal combination vaccines for bacterial meningitis
GB0211118D0 (en) * 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
WO2004011027A1 (en) 2002-07-30 2004-02-05 Baxter International Inc. Chimeric multivalent polysaccharide conjugate vaccines
MXPA05001265A (en) 2002-08-02 2005-04-28 Glaxosmithkline Biolog Sa Neisserial vaccine compositions comprising a combination of antigens.
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
GB0220199D0 (en) * 2002-08-30 2002-10-09 Univ Utrecht Mutant protein and refolding method
DK2353608T3 (en) * 2002-10-11 2020-02-10 Novartis Vaccines And Diagnostics S R L Polypeptid vaccines for wide protection against hypervirulent meningococ lines
CN1401328A (en) 2002-10-18 2003-03-12 北京绿竹生物技术有限责任公司 Epidemic meningitis polyose-protein binding vaccine
PT1556477T (en) * 2002-11-01 2017-11-14 Glaxosmithkline Biologicals Sa Drying process
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
CN1168501C (en) 2002-12-27 2004-09-29 北京绿竹生物技术有限责任公司 Poly saccharide-protein combination vaccine
EP1587537B1 (en) * 2003-01-30 2012-04-11 Novartis AG Injectable vaccines against multiple meningococcal serogroups
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
CA2518669C (en) * 2003-03-13 2014-07-29 Glaxosmithkline Biologicals S.A. Purification process
WO2004083251A2 (en) 2003-03-17 2004-09-30 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
CN104225587B (en) 2003-05-07 2017-07-21 赛诺菲巴斯德公司 Multivalent meningococcal derivatized proteinpolysaccharide conjugate and vaccine
AT437633T (en) 2003-06-02 2009-08-15 Novartis Vaccines & Diagnostic Immunogenic compositions based on biodegradable micro particles containing a diphtheria and tetano toxoid
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
BRPI0411875A (en) 2003-06-23 2006-08-08 Sanofi Pasteur Inc immunization method against neisseria meningitidis serogroups a and c
KR101034055B1 (en) 2003-07-18 2011-05-12 엘지이노텍 주식회사 Light emitting diode and method for manufacturing light emitting diode
PL1961426T3 (en) * 2003-10-02 2012-03-30 Gsk Vaccines S R L Combined meningitis vaccines
AU2004277342B2 (en) * 2003-10-02 2010-12-16 Glaxosmithkline Biologicals S.A. Pertussis antigens and use thereof in vaccination
EP1706481A2 (en) 2003-12-23 2006-10-04 GlaxoSmithKline Biologicals S.A. Vaccine
GB0405787D0 (en) 2004-03-15 2004-04-21 Chiron Srl Low dose vaccines
NZ550152A (en) 2004-04-05 2009-04-30 Pfizer Prod Inc Microfluidized oil-in-water emulsions and vaccine compositions
PL1740217T3 (en) * 2004-04-30 2012-03-30 Novartis Ag Meningococcal conjugate vaccination
GB0413868D0 (en) * 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
US20060121055A1 (en) * 2004-12-06 2006-06-08 Becton, Dickinson And Company, Inc. Compositions with enhanced immunogenicity
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
GB0500787D0 (en) * 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0502095D0 (en) * 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
PL2351772T3 (en) * 2005-02-18 2017-01-31 Glaxosmithkline Biologicals Sa Proteins and nucleic acids from meningitis/sepsis-associated Escherichia coli
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
US20070184072A1 (en) * 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
TWI386222B (en) * 2005-04-08 2013-02-21 Wyeth Corp Multivalent pneumococcal polysaccharide-protein conjugate composition
JP2008540398A (en) * 2005-05-06 2008-11-20 ストックホルム ユニバーシティ Immunogen for meningitis type A vaccine
NZ564371A (en) * 2005-06-27 2010-05-28 Glaxosmithkline Biolog Sa Immunogenic composition comprising Hib saccharide conjugate and at least two further bacterial saccharide conjugates
CN1709505B (en) 2005-07-13 2010-06-16 北京绿竹生物制药有限公司 Polyvalent bacteria capsule polysaccharide-protein conjugate combined vaccine
BRPI0615420A2 (en) 2005-09-01 2011-05-17 Novartis Vaccines & Diagnostic multiple vaccination including serogroup c meningococcus
WO2007028408A1 (en) 2005-09-05 2007-03-15 Glaxosmithkline Biologicals S.A. Serum bactericidal assay for n. meningitidis specific antisera
GB0522765D0 (en) * 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
CN101374548B (en) * 2005-12-22 2013-05-01 葛兰素史密丝克莱恩生物有限公司 Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
CA2633789A1 (en) * 2005-12-23 2007-06-28 Glaxosmithkline Biologicals Sa Conjugate vaccines
KR101711903B1 (en) * 2006-03-17 2017-03-03 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 Methods for preparing complex multivalent immunogenic conjugates
AR060187A1 (en) 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa immunogenic composition
JP2009531387A (en) * 2006-03-30 2009-09-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Immunogenic composition
GB0607088D0 (en) * 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
EP2044104A2 (en) 2006-06-29 2009-04-08 Novartis AG Polypeptides from neisseria meningitidis
US7491517B2 (en) 2006-07-19 2009-02-17 Jeeri R Reddy Method of producing meningococcal meningitis vaccine for Neisseria meningitidis serotypes A,C,Y, and W-135
BRPI0714714A2 (en) 2006-07-21 2013-04-09 Univ California compositions of human endogenous retrovirus polypeptide and (herv) and their methods and uses
DK2066344T3 (en) * 2006-09-07 2011-09-05 Glaxosmithkline Biolog Sa Inactivated Poliovirus combination vaccine
GB0700136D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0700135D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
JP4858611B2 (en) 2007-03-14 2012-01-18 コニカミノルタビジネステクノロジーズ株式会社 Information embedding method, program thereof, and information embedding device
CN101687028A (en) 2007-05-02 2010-03-31 葛兰素史密丝克莱恩生物有限公司 Vaccine
CN101678094B (en) 2007-06-04 2014-08-27 诺华股份有限公司 Formulation of meningitis vaccines
CN101784282B (en) * 2007-06-26 2015-07-08 葛兰素史密丝克莱恩生物有限公司 Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
EP2328613A1 (en) 2008-08-28 2011-06-08 GlaxoSmithKline Biologicals S.A. Vaccine
GB0816447D0 (en) * 2008-09-08 2008-10-15 Glaxosmithkline Biolog Sa Vaccine
US8259461B2 (en) * 2008-11-25 2012-09-04 Micron Technology, Inc. Apparatus for bypassing faulty connections
CN102596254B (en) * 2009-09-30 2016-10-19 诺华股份有限公司 Staphylococcus aureus 5 type and the coupling of CP8
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
GB201003922D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
US9365624B2 (en) * 2010-03-11 2016-06-14 Glaxosmithkline Biologicals, S.A. Vaccine
JP5144836B2 (en) * 2010-06-11 2013-02-13 パナソニック株式会社 Speech listening evaluation system, method and program thereof
RU2636350C2 (en) * 2011-11-07 2017-11-22 Новартис Аг MOLECULE CONTAINING spr0096 AND spr2021
GB2495341B (en) * 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
CA2863178A1 (en) * 2012-01-30 2013-08-08 Serum Institute Of India Ltd. Immunogenic composition
KR20150021933A (en) * 2012-05-22 2015-03-03 노파르티스 아게 Meningococcus serogroup x conjugate
WO2014001328A1 (en) 2012-06-25 2014-01-03 Nadiro A/S A lifeboat deployment unit
PT2928489T (en) * 2012-12-05 2019-05-28 Glaxosmithkline Biologicals Sa Immunogenic composition
GB201310008D0 (en) * 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
CN108064174A (en) * 2014-08-05 2018-05-22 葛兰素史密丝克莱恩生物有限公司 The carrier molecule of antigen
GB201518684D0 (en) * 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
PE20191107A1 (en) * 2017-01-31 2019-08-26 Pfizer Neisseria meningitidis compositions and respective methods

Also Published As

Publication number Publication date
PE20110096A1 (en) 2011-03-07
SI1896063T1 (en) 2012-03-30
EP3009146A1 (en) 2016-04-20
NZ564606A (en) 2010-10-29
ES2340711T3 (en) 2010-06-08
PE20070163A1 (en) 2007-03-01
MA29603B1 (en) 2008-07-01
AU2006263965A1 (en) 2007-01-04
JP2008543908A (en) 2008-12-04
US10245317B2 (en) 2019-04-02
LT2351578T (en) 2017-04-10
DE602006013313D1 (en) 2010-05-12
IL188046A (en) 2012-03-29
NO20076363L (en) 2008-03-26
HUE045482T2 (en) 2019-12-30
IL213795A (en) 2013-05-30
US20100215686A1 (en) 2010-08-26
US9358279B2 (en) 2016-06-07
KR101532068B1 (en) 2015-06-29
AR053935A1 (en) 2007-05-23
JP2013018798A (en) 2013-01-31
MX2007016402A (en) 2008-03-07
NZ564371A (en) 2010-05-28
EP2351578A1 (en) 2011-08-03
HK1114011A1 (en) 2011-10-28
HK1116413A1 (en) 2010-09-03
AT516816T (en) 2011-08-15
CN102526723A (en) 2012-07-04
IL222346A (en) 2015-07-30
WO2007000342A3 (en) 2007-05-31
WO2007000322A1 (en) 2007-01-04
JP5718960B2 (en) 2015-05-13
AU2010203115C1 (en) 2013-05-02
BRPI0612655A2 (en) 2010-11-30
NZ564607A (en) 2011-06-30
CN102218138A (en) 2011-10-19
AT462444T (en) 2010-04-15
AR056396A1 (en) 2007-10-10
EA200702575A1 (en) 2008-06-30
AT536884T (en) 2011-12-15
US9486515B2 (en) 2016-11-08
BRPI0612656A2 (en) 2010-11-30
PL2878307T3 (en) 2020-01-31
CY1111827T1 (en) 2015-10-07
JP5965512B2 (en) 2016-08-03
EP1896065B1 (en) 2011-07-20
AU2006263963B2 (en) 2010-05-13
EA012528B1 (en) 2009-10-30
EP2878307A1 (en) 2015-06-03
TWI477283B (en) 2015-03-21
PE20070499A1 (en) 2007-05-21
BRPI0612669B1 (en) 2019-08-13
CN103083657A (en) 2013-05-08
CA2612963A1 (en) 2007-01-04
PT1896065E (en) 2011-08-31
BRPI0612655A8 (en) 2018-01-30
EP1896061B1 (en) 2019-06-12
PL2351578T3 (en) 2017-07-31
EP2878307B1 (en) 2019-07-24
EP1896062A1 (en) 2008-03-12
LU92085I9 (en) 2019-01-04
HRP20100211T1 (en) 2010-05-31
US8883163B2 (en) 2014-11-11
TW200738259A (en) 2007-10-16
AP2436A (en) 2012-08-31
ES2377075T3 (en) 2012-03-22
IL188046D0 (en) 2008-03-20
KR20080024222A (en) 2008-03-17
NO344452B1 (en) 2019-12-09
CA2611964A1 (en) 2007-01-04
US20170065714A1 (en) 2017-03-09
JP2008543905A (en) 2008-12-04
EA012214B1 (en) 2009-08-28
HK1116414A1 (en) 2012-05-25
DK1896061T3 (en) 2019-08-26
IL187924D0 (en) 2008-03-20
DK2878307T3 (en) 2019-10-07
JP5769688B2 (en) 2015-08-26
BRPI0612670B1 (en) 2020-04-28
IL188072A (en) 2017-07-31
CA2611964C (en) 2016-11-08
HK1206587A1 (en) 2016-01-15
CA2611960A1 (en) 2007-01-04
JP2008543904A (en) 2008-12-04
IL213718D0 (en) 2011-07-31
PE20070123A1 (en) 2007-02-08
TW201414490A (en) 2014-04-16
WO2007000341A3 (en) 2007-05-31
UA95237C2 (en) 2011-07-25
CA2612963C (en) 2016-10-18
AU2006263936A1 (en) 2007-01-04
EA200702576A1 (en) 2008-06-30
WO2007000342A2 (en) 2007-01-04
HRP20110567T1 (en) 2011-09-30
JP2008543909A (en) 2008-12-04
US20150044253A1 (en) 2015-02-12
BRPI0612669A2 (en) 2010-11-30
UA95238C2 (en) 2011-07-25
PT2283857T (en) 2019-10-24
US8846049B2 (en) 2014-09-30
IL187924A (en) 2011-11-30
WO2007000314A3 (en) 2007-05-31
BRPI0612654A2 (en) 2012-10-02
EP2283857B1 (en) 2019-07-24
EP1896063A1 (en) 2008-03-12
US20090136541A1 (en) 2009-05-28
LU92085I2 (en) 2012-12-19
MX2007016237A (en) 2008-03-07
PT1896062E (en) 2010-05-17
DK1896062T3 (en) 2010-06-28
US8329184B2 (en) 2012-12-11
DK1896063T3 (en) 2012-03-19
SI2283857T1 (en) 2019-11-29
CN102526723B (en) 2017-07-07
US9931397B2 (en) 2018-04-03
SI2351578T1 (en) 2017-05-31
SI1896065T2 (en) 2014-12-31
AU2006263963A1 (en) 2007-01-04
CN103083657B (en) 2016-06-08
EA012506B1 (en) 2009-10-30
AU2006263964B2 (en) 2010-05-20
SI1896065T1 (en) 2011-10-28
SI1896061T1 (en) 2019-10-30
MA29602B1 (en) 2008-07-01
US20180064806A1 (en) 2018-03-08
US20200000911A1 (en) 2020-01-02
JP5297800B2 (en) 2013-09-25
ES2377075T5 (en) 2016-04-29
DK2351578T3 (en) 2017-04-24
US20090252759A1 (en) 2009-10-08
EP1896062B1 (en) 2010-03-31
EP1896061A2 (en) 2008-03-12
MY148110A (en) 2013-02-28
WO2007000314A2 (en) 2007-01-04
HRP20110567T4 (en) 2015-01-16
JP5731737B2 (en) 2015-06-10
CA2611960C (en) 2015-05-05
TWI537001B (en) 2016-06-11
HUE046905T2 (en) 2020-03-30
EP2351578B1 (en) 2017-01-18
KR101408113B1 (en) 2014-06-16
AP200704274A0 (en) 2007-12-31
KR101351873B1 (en) 2014-02-17
TWI407970B (en) 2013-09-11
KR20080018226A (en) 2008-02-27
EP1896063B2 (en) 2016-03-02
IL213718A (en) 2013-07-31
PT1896063E (en) 2012-02-13
US20080199490A1 (en) 2008-08-21
AU2006263944B2 (en) 2012-03-01
ES2747025T3 (en) 2020-03-09
JP2015134829A (en) 2015-07-27
SI2878307T1 (en) 2019-11-29
KR20080025184A (en) 2008-03-19
WO2007000341A2 (en) 2007-01-04
AU2010212417A1 (en) 2010-09-09
PL1896063T3 (en) 2012-04-30
EP2201961B1 (en) 2018-01-24
HUE047211T2 (en) 2020-04-28
TWI422386B (en) 2014-01-11
JP2013107913A (en) 2013-06-06
EP1896063B1 (en) 2011-12-14
NO342815B1 (en) 2018-08-13
ES2621780T3 (en) 2017-07-05
ES2741529T3 (en) 2020-02-11
AU2010203115B2 (en) 2012-03-15
TW200730187A (en) 2007-08-16
CY1109996T1 (en) 2014-09-10
BRPI0612670A2 (en) 2010-11-30
EP1896065A2 (en) 2008-03-12
ES2662651T3 (en) 2018-04-09
AU2006263964A1 (en) 2007-01-04
TW201336507A (en) 2013-09-16
MX2007016405A (en) 2008-03-07
PE20142165A1 (en) 2015-01-09
SI1896062T1 (en) 2010-07-30
MX2007016236A (en) 2008-03-07
PL1896065T3 (en) 2011-12-30
IL213795D0 (en) 2011-07-31
US10166287B2 (en) 2019-01-01
EP1896064A2 (en) 2008-03-12
WO2007000343A2 (en) 2007-01-04
EA200702577A1 (en) 2008-06-30
KR20080018216A (en) 2008-02-27
PT2351578T (en) 2017-04-07
JP5280199B2 (en) 2013-09-04
KR20130122810A (en) 2013-11-08
DK1896065T3 (en) 2011-08-29
US20190298822A1 (en) 2019-10-03
BRPI0612656A8 (en) 2018-01-23
EP1896065B2 (en) 2014-09-03
CY1112698T1 (en) 2016-02-10
IL214657D0 (en) 2011-09-27
NL300549I2 (en) 2017-01-03
AU2006263965B2 (en) 2012-09-13
EA200702574A1 (en) 2008-06-30
PT1896061T (en) 2019-08-01
WO2007000342A8 (en) 2008-07-10
KR20130086087A (en) 2013-07-30
MA29993B1 (en) 2008-12-01
EA013374B1 (en) 2010-04-30
CA2612957A1 (en) 2007-01-04
PL1896061T3 (en) 2020-02-28
PL1896065T5 (en) 2014-12-31
HUE031380T2 (en) 2017-07-28
IL188045D0 (en) 2008-03-20
JP2008543907A (en) 2008-12-04
KR20080030577A (en) 2008-04-04
ES2750243T3 (en) 2020-03-25
US8398983B2 (en) 2013-03-19
CA2612980C (en) 2019-01-15
AR056397A1 (en) 2007-10-10
US20090041802A1 (en) 2009-02-12
HRP20170457T1 (en) 2017-05-19
NO20076343L (en) 2008-03-25
PT2878307T (en) 2019-10-24
PL1896062T3 (en) 2010-08-31
US8431136B2 (en) 2013-04-30
NZ564605A (en) 2011-01-28
NO20076302L (en) 2008-03-26
CY1118646T1 (en) 2017-07-12
MY147490A (en) 2012-12-14
DK1896065T4 (en) 2014-10-20
MY147783A (en) 2013-01-31
HRP20120102T1 (en) 2012-02-29
JP2013209395A (en) 2013-10-10
AU2006263936B2 (en) 2010-05-20
PL2283857T3 (en) 2020-02-28
US20130171188A1 (en) 2013-07-04
WO2007000343A3 (en) 2007-05-31
DK2283857T3 (en) 2019-10-28
KR101351870B1 (en) 2014-02-17
CA2612957C (en) 2016-07-19
KR101321056B1 (en) 2013-10-30
AU2006263944A1 (en) 2007-01-04
EP2201961A1 (en) 2010-06-30
NZ590204A (en) 2012-02-24
NO20076350L (en) 2008-03-26
PE20110072A1 (en) 2011-02-04
NZ564370A (en) 2011-10-28
MA29569B1 (en) 2008-06-02
CA2612980A1 (en) 2007-01-04
US20080193476A1 (en) 2008-08-14
AU2010203115A1 (en) 2010-08-12
US20130004532A1 (en) 2013-01-03
WO2007000327A1 (en) 2007-01-04
JP5037503B2 (en) 2012-09-26
US9789179B2 (en) 2017-10-17
EP1896066A2 (en) 2008-03-12
EP2283857A1 (en) 2011-02-16
KR101359953B1 (en) 2014-02-21
MX2007016403A (en) 2008-03-07

Similar Documents

Publication Publication Date Title
TWI340137B (en) Preparation process
PL1968631T3 (en) Vaccine
GB0427747D0 (en) Process
GB0416001D0 (en) Process
AT516816T (en) Process for the production of vaccines
EP2032031A4 (en) Improved process
PL1754581T3 (en) Method for manufacturing panels
ZA200606877B (en) Process
GB0409490D0 (en) Process
ZA200800770B (en) Process for producing propylene oxide
SI2546205T1 (en) Method for producing vials
GB0625214D0 (en) Process
GB0418046D0 (en) Eantioselective process
EP1864785A4 (en) Seterolithography method
PT1816117E (en) Method for manufacturing nitrobenzole
GB0503836D0 (en) Method
GB0504436D0 (en) Vaccine
GB0404793D0 (en) Process
GB0522765D0 (en) Combination vaccine manufacture
IL188600D0 (en) Method for preparing esomeprazole
AT439198T (en) Kryofluide supported manufacturing process
EP1828170A4 (en) Process for preparing voriconazole
ZA200802598B (en) Chemo-immunotherapy method
GB0511649D0 (en) Method
GB0611210D0 (en) Process

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed